Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Menopause01:28

Menopause

5.2K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.2K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

901
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
901
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

368
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
368
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

1.3K
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of epigenetic age acceleration with MRI biomarkers of aging and Alzheimer's disease neurodegeneration.

Aging·2026
Same author

Eye movement features are associated with cognitive and mobility decline.

Journal of Alzheimer's disease : JAD·2026
Same author

Plasma lipids connecting olfaction with cognition and physical function.

Scientific reports·2026
Same author

Plasma Phosphorylated Tau 217 and Incident Mild Cognitive Impairment and Dementia in Older Women.

JAMA network open·2026
Same author

Epigenetic Clocks of Biological Aging and Risk of Incident Mild Cognitive Impairment and Dementia: The Women's Health Initiative Memory Study.

Aging cell·2026
Same author

Genetic modifiers of APOE-ε4-associated cognitive decline.

Nature communications·2026
Same journal

Timed melatonin administration increases territorial but not non-territorial aggression in female Siberian hamsters.

Hormones and behavior·2026
Same journal

Neuroendocrine signatures of urban aggression: Arginine vasotocin (AVT) receptor distribution and expression in male song sparrow (Melospzia melodia) brain.

Hormones and behavior·2026
Same journal

Hormones, sex differences, and autism: From single-cause theories to integrated developmental systems.

Hormones and behavior·2026
Same journal

Androgen receptor activation is involved in maintaining goal-directed behavior in levonorgestrel-treated female rats.

Hormones and behavior·2026
Same journal

Sleep hygiene behaviors and actigraphic sleep: a pilot analysis of gender differences.

Hormones and behavior·2026
Same journal

Neuroendocrine basis of affective behavior: what we can learn from differences in sex development (DSD).

Hormones and behavior·2026
See all related articles

Related Experiment Video

Updated: Apr 13, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.1K

Postmenopausal hormone therapy and cognition.

Anna C McCarrey1, Susan M Resnick1

  • 1Laboratory of Behavioral Neuroscience, National Institute on Aging, NIH, Baltimore, MD, 21224, USA.

Hormones and Behavior
|May 4, 2015
PubMed
Summary
This summary is machine-generated.

Hormone therapy (HT) may increase dementia risk in older women, contrary to earlier beliefs. Estrogen

Keywords:
AgingCognitionEstrogenHormone therapyMenopause

More Related Videos

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

13.2K
Place and Response Learning in the Open-field Tower Maze
08:31

Place and Response Learning in the Open-field Tower Maze

Published on: October 28, 2015

11.0K

Related Experiment Videos

Last Updated: Apr 13, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.1K
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

13.2K
Place and Response Learning in the Open-field Tower Maze
08:31

Place and Response Learning in the Open-field Tower Maze

Published on: October 28, 2015

11.0K

Area of Science:

  • Neuroscience and Endocrinology
  • Cognitive Health and Aging

Background:

  • Estrogen-containing hormone therapy (HT) was previously used for menopausal symptom relief and age-related disease prevention.
  • Observational studies suggested potential cognitive benefits of HT, but randomized trials yielded mixed results.
  • The Women's Health Initiative (WHI) and WHI Memory Study (WHIMS) provided crucial data on HT's cognitive effects.

Purpose of the Study:

  • To review the effects of hormone therapy on cognition and dementia risk in menopausal women.
  • To examine findings from the WHI Memory Study (WHIMS) regarding HT and cognitive outcomes.
  • To explore the 'critical window hypothesis' and the influence of other health risks on HT's cognitive impact.

Main Methods:

  • Review of existing literature and large-scale randomized clinical trial data, including the WHI Memory Study (WHIMS).
  • Analysis of cognitive outcomes in naturally menopausal and surgically induced menopausal women.
  • Consideration of factors such as age at menopause and co-existing health conditions.

Main Results:

  • Contrary to expectations, the WHIMS showed an increased dementia risk and poorer cognitive outcomes in older postmenopausal women randomized to HT.
  • The 'critical window hypothesis' suggests estrogen therapy may be more effective when initiated closer to menopause.
  • Adverse cognitive effects of HT appear more pronounced in women with pre-existing health risks like diabetes or lower global cognition.

Conclusions:

  • Hormone therapy, particularly in older postmenopausal women, may increase dementia risk.
  • The timing of hormone therapy initiation (critical window) and individual health status are crucial factors.
  • Further research is needed to clarify optimal clinical treatments and personalized approaches to hormone therapy for cognitive health.